Alaunos Therapeutics, Inc. (TCRT) stock
TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.66+0.06 (+3.75%)
Close on Nov 17, 2026Market cap $4.22MP/E –Yield –
Alaunos Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Alaunos Therapeutics's ebitda for the twelve months ending Sep 30, 2017 was -$50.85M. For fiscal 2016 it was -$165.02M. The highest annual figure on record is -$11.79M in fiscal 2009.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | -$165.02M | – |
| FY2015 | Dec 31, 2015 | -$119.74M | – |
| FY2014 | Dec 31, 2014 | -$43.04M | – |
| FY2013 | Dec 31, 2013 | -$56.98M | – |
| FY2012 | Dec 31, 2012 | -$101.51M | – |
| FY2011 | Dec 31, 2011 | -$71.13M | – |
| FY2010 | Dec 31, 2010 | -$24.36M | – |
| FY2009 | Dec 31, 2009 | -$11.79M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2018 | Sep 30, 2018 | -$12.41M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.08M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.99M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.93M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.89M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.05M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.84M | – |
| Q2 FY2016 | Jun 30, 2016 | -$131.16M | – |
See a number that looks wrong?